Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success

A late-stage trial found Moderna and Merck’s cancer vaccine, when paired with Keytruda, reduced the risk of death and melanoma recurrence by 42% in melanoma patients. The result is encouraging clinical evidence, though the article provides no further trial details or market reaction.